^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | VBI-1901 (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
Published date:
06/08/2021
Excerpt:
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate for the treatment of recurrent glioblastoma (GBM) patients with first tumor recurrence.
